173 related articles for article (PubMed ID: 16790789)
21. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.
Kelly-Cirino CD; Mantis NJ
Infect Immun; 2009 Nov; 77(11):4859-67. PubMed ID: 19703971
[TBL] [Abstract][Full Text] [Related]
22. Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins.
Rivera J; Cordero RJ; Nakouzi AS; Frases S; Nicola A; Casadevall A
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):19002-7. PubMed ID: 20956325
[TBL] [Abstract][Full Text] [Related]
23. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.
Little SF; Novak JM; Lowe JR; Leppla SH; Singh Y; Klimpel KR; Lidgerding BC; Friedlander AM
Microbiology (Reading); 1996 Mar; 142 ( Pt 3)():707-715. PubMed ID: 8868446
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody therapies against anthrax.
Chen Z; Moayeri M; Purcell R
Toxins (Basel); 2011 Aug; 3(8):1004-19. PubMed ID: 22069754
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
Park YS; Lee JH; Hung CF; Wu TC; Kim TW
Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
[TBL] [Abstract][Full Text] [Related]
26. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
[TBL] [Abstract][Full Text] [Related]
27. A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.
Moayeri M; Leysath CE; Tremblay JM; Vrentas C; Crown D; Leppla SH; Shoemaker CB
J Biol Chem; 2015 Mar; 290(10):6584-95. PubMed ID: 25564615
[TBL] [Abstract][Full Text] [Related]
28. [Characteristics of the immune response to the lethal toxin of Bacillus anthracis].
Belova EV; Kolesnikov AV; Zakharova MIu; Dubileĭ SA; Diatlov IA; Shemiakin IG
Bioorg Khim; 2008; 34(5):639-44. PubMed ID: 19060938
[TBL] [Abstract][Full Text] [Related]
29. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
[TBL] [Abstract][Full Text] [Related]
30. A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen.
Oscherwitz J; Yu F; Cease KB
Infect Immun; 2009 Dec; 77(12):5509-18. PubMed ID: 19805525
[TBL] [Abstract][Full Text] [Related]
31. Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor.
Thullier P; Avril A; Mathieu J; Behrens CK; Pellequer JL; Pelat T
PLoS One; 2013; 8(5):e65855. PubMed ID: 23741517
[TBL] [Abstract][Full Text] [Related]
32. Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice.
Moayeri M; Tremblay JM; Debatis M; Dmitriev IP; Kashentseva EA; Yeh AJ; Cheung GY; Curiel DT; Leppla S; Shoemaker CB
Clin Vaccine Immunol; 2016 Jan; 23(3):213-8. PubMed ID: 26740390
[TBL] [Abstract][Full Text] [Related]
33. A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against
Majumder S; Das S; Somani VK; Makam SS; Kingston JJ; Bhatnagar R
Front Immunol; 2019; 10():498. PubMed ID: 30941133
[TBL] [Abstract][Full Text] [Related]
34. Mapping of antibody responses to the protective antigen of Bacillus anthracis by flow cytometric analysis.
Reed DS; Smoll J; Gibbs P; Little SF
Cytometry; 2002 Sep; 49(1):1-7. PubMed ID: 12210604
[TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis.
Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R
Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802
[TBL] [Abstract][Full Text] [Related]
36. A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion.
Mechaly A; Levy H; Epstein E; Rosenfeld R; Marcus H; Ben-Arie E; Shafferman A; Ordentlich A; Mazor O
J Biol Chem; 2012 Sep; 287(39):32665-73. PubMed ID: 22869370
[TBL] [Abstract][Full Text] [Related]
37. Domain specificity of the human antibody response to Bacillus anthracis protective antigen.
Reason DC; Ullal A; Liberato J; Sun J; Keitel W; Zhou J
Vaccine; 2008 Jul; 26(32):4041-7. PubMed ID: 18565627
[TBL] [Abstract][Full Text] [Related]
38. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
Welkos S; Little S; Friedlander A; Fritz D; Fellows P
Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax.
Winterroth L; Rivera J; Nakouzi AS; Dadachova E; Casadevall A
Infect Immun; 2010 Jun; 78(6):2890-8. PubMed ID: 20385755
[TBL] [Abstract][Full Text] [Related]
40. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin.
Little SF; Leppla SH; Friedlander AM
Infect Immun; 1990 Jun; 58(6):1606-13. PubMed ID: 2111283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
